ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstracts tagged "pain"

  • Abstract Number: 0405 • ACR Convergence 2020

    Disease Activity and Quality-of-Life Outcomes in Patients with Behçet’s Syndrome Who Achieved and Maintained Oral Ulcer Complete Response with Apremilast Treatment

    Gülen Hatemi1, Alfred Mahr2, Mitsuhiro Takeno3, Doyoung Kim4, Melike Melikoğlu1, Sue Cheng5, Sven Richter5, Michele Brunori6, Maria Paris5, Mindy Chen5 and Yusuf Yazici7, 1Istanbul University‒Cerrahpaşa, Cerrahpaşa Medical School and Behçet’s Disease Research Center, Istanbul, Turkey, 2Cantonal Hospital St. Gallen, St. Gallen, Switzerland, 3Nippon Medical School, Graduate School of Medicine, Tokyo, Japan, 4Yonsei University College of Medicine and Severance Hospital, Seoul, Republic of Korea, 5Amgen Inc., Thousand Oaks, 6Amgen Europe GmbH, Rotkreuz, Switzerland, 7New York University School of Medicine, New York

    Background/Purpose: Recurrent, painful oral ulcers (OU) are common symptoms of Behçet’s syndrome that can impact daily activities and impair quality of life (QoL) (Kokturk A.…
  • Abstract Number: 0899 • ACR Convergence 2020

    Secukinumab Provides Significant Improvement of Spinal Pain and Lowers Disease Activity in Patients with Axial Spondyloarthritis: 24-week Results from a Randomized Controlled Phase 3b Trial

    Denis Poddubnyy1, Effie Pournara2, Agnieszka Zielinska3, Asta Baranauskaite4, Alejandro Muñoz Jiménez5, Sanchayita Sadhu6, Barbara Schulz2, Michael Rissler2, Chiara Perella2 and Helena Marzo-Ortega7, 1Charité – Universitätsmedizin Berlin, Berlin, Germany, 2Novartis Pharma AG, Basel, Switzerland, 3Medycyna Kliniczna, Warszawa, Poland, 4Lithuanian University of Health Sciences, Kaunas, Lithuania, 5H. U. Virgen del Rocío (Sevilla), Sevilla, Spain, 6Novartis Healthcare Private Limited, Hyderabad, Telangana, India, 7The University of Leeds, Leeds Institute for Rheumatic and Musculoskeletal Medicine, NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals Trust, Leeds, UK, Leeds, United Kingdom

    Background/Purpose: SKIPPAIN (NCT03136861) is the first randomized controlled study involving a biological disease modifying antirheumatic drug, with spinal pain as the primary endpoint as early…
  • Abstract Number: 1230 • ACR Convergence 2020

    Curcumin: Prevalence and Perceived Efficacy in the Treatment of Rheumatoid and Psoriatic Arthritis

    Neha Bhaskar1, Lilian Otalora Rojas2, Tara Jehu1, Shazia Beg1 and Neha Bhanusali1, 1University of Central Florida College of Medicine, orlando, 2University of Central Florida HCA Healthcare GME, Orlando

    Background/Purpose: Ancient Eastern medicine has valued the Curcuma longa (turmeric) plant for its powerful medicinal properties. Curcumin is suggested to possess potent anti-inflammatory, antioxidant, antimicrobial,…
  • Abstract Number: 1644 • ACR Convergence 2020

    Radiographic Exclusionary Findings During Screening for Three Phase III Trials of Subcutaneous Tanezumab in Patients with Moderate to Severe Hip or Knee Osteoarthritis

    Ali Guermazi1, Frank Roemer2, Andrew Kompel1, Luis Diaz3, Michel Crema4, Mark Brown5, Anne Hickman5, Glenn Pixton6, Lars Viktrup7, Robert Fountaine5, Aimee Burr5, Sarah Sherlock5 and Christine West8, 1Boston University School of Medicine, Boston, MA, 2Boston University School of Medicine, Boston, MA, and Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany, Erlangen, Germany, 3Boston Veteran Affairs Healthcare System, Boston, MA, 4Boston University School of Medicine, Paris, France, 5Pfizer Inc., Groton, CT, 6Pfizer Inc., Morrisville, NC, 7Eli Lilly and Company, Indianapolis, IN, 8Pfizer Inc, Groton, CT

    Background/Purpose: Tanezumab is a nerve growth factor monoclonal antibody in development for osteoarthritis (OA). Following a clinical hold due to concerns around adverse joint events,…
  • Abstract Number: 1960 • ACR Convergence 2020

    Cost-effectiveness of Surgical and Non-Surgical Weight Loss Programs for Morbidly Obese Patients with Knee Osteoarthritis

    Valia Leifer1, Jeffrey Katz2, Faith Selzer3, Tuhina Neogi4, Jamie Collins5 and Elena Losina2, 1The Orthopaedic and Arthritis Center for Outcomes Research (OrACORe) at Brigham and Women's Hospital, Boston, 2Harvard Medical School / The Orthopaedic and Arthritis Center for Outcomes Research (OrACORe) at Brigham and Women's Hospital, Boston, MA, 3The Orthopaedic and Arthritis Center for Outcomes Research (OrACORe) at Brigham and Women's Hospital, Amesbury, MA, 4Boston University School of Medicine, Boston, MA, 5The Orthopaedic and Arthritis Center for Outcomes Research (OrACORe) at Brigham and Women's Hospital, Boston, MA

    Background/Purpose: Growing numbers of knee osteoarthritis (KOA) patients are morbidly obese (BMI ≥ 35 kg/m2). Evolving evidence suggests weight reduction may delay the structural progression…
  • Abstract Number: 0438 • ACR Convergence 2020

    Pharmacist-Led Multidisciplinary Approach to Opioid Tapering in a Large Private Rheumatology Practice

    Jessica Farrell1, Mitchell Miller1, Kelsey Hennig2, Kelley Powers3, Sooyeon Kwon4, Denae Moyer5, Kathryn French5, Angela Citta5 and Jacqueline Cleary1, 1Albany College of Pharmacy and Health Sciences, Albany, NY, 2Albany College of Pharmacy and Health Sciences, New Lebanon, NY, 3The Center for Rheumatology, Delanson, NY, 4Albany Stratton VA Hospital, Loudonville, NY, 5Albany College of Pharmacy and Health Sciences, Albany

    Background/Purpose: With the evolution of DMARDs, the need for opioids in the treatment of rheumatic diseases has decreased. However, rheumatology professionals are often presented with…
  • Abstract Number: 0940 • ACR Convergence 2020

    In Patients with Inflammatory Arthritides Central Pain Sensitization Is Strictly Associated with Functional Disability

    Giovanni Adami1, Angelo Fassio1, Elisabetta Gerratana2, Alessandro Giollo1, Camilla Benini1, Luca Idolazzi1, Elisabetta Vantaggiato1, Davide Gatti1 and Maurizio Rossini1, 1Rheumatology Unit, University of Verona, Verona, Italy, 2Rheumatology Unit, University of Messina, Messina, Italy

    Background/Purpose: Long-term nociceptive pain, as in inflammatory arthritides, can cause Central Sensitization (CS) to pain. CS Inventory (CSI) is a validated screening instrument for clinicians to…
  • Abstract Number: 1234 • ACR Convergence 2020

    Noninflammatory Pain Is a Frequent Phenomenon in Rheumatoid Arthritis and Responds Well to Treatment with Sarilumab

    Ernest Choy1, Vivian Bykerk2, Yvonne Lee3, Gregory St John4, Hubert van Hoogstraten5, Kerri Ford6, Amy Praestgaard6 and Anthony Sebba7, 1CREATE Centre, Cardiff University, Cardiff, Wales, United Kingdom, 2Hospital for Special Surgery, New York, NY, 3Northwestern University Feinberg School of Medicine, Chicago, IL, 4Regeneron Pharmaceuticals Inc, Tarrytown, NY, 5Sanofi, Bridgewater, NJ, 6Sanofi, Cambridge, MA, 7Arthritis Associates, Palm Harbor, Tampa, FL

    Background/Purpose: Inflammation is a key driver of pain in rheumatoid arthritis (RA). However, in some patients the level of pain exceeds what would be expected…
  • Abstract Number: 1645 • ACR Convergence 2020

    Placebo Group Responses in Clinical Trials of Patients with Osteoarthritis: Data from the Tanezumab Development Program

    Luana Colloca1, Robert Dworkin2, John Farrar3, Leslie Tive4, Ed Whalen5, Jerry Yang4, Lars Viktrup6, Mark Brown7, Christine West7 and Kenneth Verburg8, 1University of Maryland, Baltimore, 2University of Rochester School of Medicine and Dentistry, Rochester, NY, 3University of Pennsylvania, Philadelphia, PA, 4Pfizer Inc, New York, NY, 5Pfizer Inc, New York, 6Eli Lilly and Company, Indianapolis, IN, 7Pfizer Inc, Groton, CT, 8Pfizer Inc, Groton

    Background/Purpose: The level of placebo group response in clinical trials for chronic pain conditions is a concern for the development of novel analgesics1. Here, we…
  • Abstract Number: 1968 • ACR Convergence 2020

    Cathepsin S Gene Expression Measured in the Peripheral Blood of Osteoarthritic Patients Prior to Surgery as a Biomarker of Post-operative Pain Development

    Elena Tchetina1, Kseniya Glemba1, Galina Markova1, Maksim Makarov1 and Aleksandr Lila1, 1Nasonova Research Institute of Rheumatology, Moscow, Russia

    Background/Purpose: Osteoarthritis (OA) is a chronic rheumatic disease, which involves pain, limited inflammation, and local destruction of the knee joint. OA pain is a major…
  • Abstract Number: 0534 • ACR Convergence 2020

    National Variation and Factors Associated with Long-term Opioid Use for Non-cancer Pain in the First Year of Use

    Meghna Jani1, Belay Yimer1, Therese Sheppard1, Mark Lunt1 and William Dixon1, 1Centre for Epidemiology Versus Arthritis, University of Manchester, Manchester, United Kingdom

    Background/Purpose: Physician prescribing behaviour has been described as a key driver of rising opioid prescriptions and long-term opioid use. However, the effect of prescribers requires…
  • Abstract Number: 0942 • ACR Convergence 2020

    Use of Medical Cannabis by Patients with Fibromyalgia: A Prospective Cross-sectional Study

    Mary-Ann Fitzcharles1, Emmanouil Rampakakis2, Yoram Shir1, John Sampalis2, Martin Cohen1, Michael Starr1 and Winfried Häuser3, 1McGill University, montreal, Canada, 2JSS Medical Research, St-Laurent, QC, Canada, 3Technische Universität München, Munich, Germany

    Background/Purpose: Treatment strategies for chronic widespread pain (CWP)/fibromyalgia (FM) are imperfect with only a modest effect from medications. Due to the many symptoms experienced by…
  • Abstract Number: 1237 • ACR Convergence 2020

    Pain and Other Patient-Reported Outcomes in Patients with Rheumatoid Arthritis Who Did or Did Not Achieve Treatment Response Based on Improvement in Swollen Joints in Tocilizumab Clinical Trials

    Anthony Sebba1, Jian Han2 and Shalini V. Mohan2, 1Arthritis Associates, Palm Harbor, Tampa, FL, 2Genentech, South San Francisco, CA

    Background/Purpose: Recent data suggest that rheumatoid arthritis (RA) pain may be noninflammatory and inflammatory, and improvement in pain scores and other patient-reported outcomes (PROs) may…
  • Abstract Number: 1646 • ACR Convergence 2020

    Use of Prescription Nonsteroidal Anti-inflammatory Drugs (NSAIDs) in Adults with Hip/Knee Osteoarthritis (OA) at Increased Risk for NSAID-related Adverse Events

    Jayeshkumar Patel1, Wenhui Wei2, Raveendhara Bannuru3, Ravi Iyer4, Nazneen Fatima Shaikh1, Traci LeMasters1, Chibuzo Iloabuchi1, Degang Wang2 and Usha Sambamoorthi1, 1West Virginia University School of Pharmacy, Morgantown, WV, 2Regeneron Pharmaceuticals, Tarrytown, NY, 3Tufts Medical Center, Boston, MA, 4Teva Pharmaceutical Industries, West Chester, PA

    Background/Purpose: NSAIDs are commonly used for OA pain, but the benefits of pain relief must be carefully weighed against the potential risk for gastrointestinal (GI),…
  • Abstract Number: 1972 • ACR Convergence 2020

    NGF-Responsive Neurons Are Sensitized in Experimental Osteoarthritis

    Rachel Miller1, Shingo Ishihara1, Alia Obeidat1 and Anne-Marie Malfait1, 1Rush University, Chicago, IL

    Background/Purpose: Nerve growth factor (NGF) is under investigation as a promising target for osteoarthritis (OA) pain. NGF exerts its potent pro-algesic effects through sensitization of…
  • 1
  • 2
  • 3
  • …
  • 15
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
This site uses cookies: Find out more.